Literature DB >> 21784684

Treatment and outcome of four cats with apocrine gland carcinoma of the anal sac and review of the literature.

James W Elliott1, Laura Blackwood.   

Abstract

Anal sac adenocarcinoma is uncommon in cats. We report the outcome of multi-modality therapy in two cats (surgery, definitive radiotherapy and systemic chemotherapy) and surgery alone in two cats. All received surgical excision of the primary tumour followed by radiotherapy and carboplatin chemotherapy in two cases. Both cats that underwent multimodal therapy developed distant metastatic disease and one developed recurrence of the primary tumour. One cat that underwent surgery alone with incomplete margins also developed rapid recurrence. Overall survival times were 89, 161 and 169 days. One cat that had complete surgical excision is still alive without recurrence 425 days postoperatively. Whilst the role of radiation in the local control of this disease is yet to be defined, clearly a more effective systemic therapy is required before such aggressive local treatment can be routinely recommended.
Copyright © 2011 ISFM and AAFP. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784684     DOI: 10.1016/j.jfms.2011.06.005

Source DB:  PubMed          Journal:  J Feline Med Surg        ISSN: 1098-612X            Impact factor:   2.015


  3 in total

1.  Apocrine gland anal sac adenocarcinoma with perineural metastasis in a cat.

Authors:  Joseph S Raleigh; Matthew R Lanza; James A Perry
Journal:  JFMS Open Rep       Date:  2018-12-03

2.  Diagnostic imaging features of normal anal sacs in dogs and cats.

Authors:  Yechan Jung; Eunseok Jeong; Sangjun Park; Jimo Jeong; Ul Soo Choi; Min-Su Kim; Namsoo Kim; Kichang Lee
Journal:  J Vet Sci       Date:  2016-09-30       Impact factor: 1.672

3.  A cat with suspected laryngeal metastasis with mucosal irregularity resulting from apocrine/salivary gland adenocarcinoma in the head.

Authors:  Aki Fujiwara-Igarashi; Koichi Shimizu; Masaki Michishita; Yoshihiko Yu; Yuji Hamamoto; Daisuke Hasegawa; Michio Fujita
Journal:  J Vet Med Sci       Date:  2017-10-11       Impact factor: 1.267

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.